NCT04557397View on ClinicalTrials.gov

Fruquintinib CYP3A Inhibitor and Inducer Study

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

October 18, 2020

Study Completion Date

October 18, 2020

Conditions
Drug Drug Interaction
Interventions
DRUG

Fruquintinib

oral VEGFR inhibitor

DRUG

Itraconazole

a synthetic triazole antifungal agent

DRUG

Rifampin

a semisynthetic antibiotic derivative of rifamycin SV

Trial Locations (1)

90630

WCCT, Cypress

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Hutchison Medipharma Limited

INDUSTRY

NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study | Biotech Hunter | Biotech Hunter